Personalized medicine is more than targeted therapeutics

That’s a message Enzo Biochem (NYSE:ENZ) wants to get out. “We are positioned extremely well for personalized medicine in the sense that as new immunoassays are recommended by the various professional societies, we are able to move them into the market very quickly because of our broad range of technology and licensure,” David Goldberg, VP [...]

Rodman starts YM at market outperform

Citing the potential of YM BioSciences’ (AMEX:YMI;TSX:YM) JAK inhibitor program, Rodman & Renshaw initiated coverage of the stock with a “market outperform/speculative risk” rating and a target price of $4 (U.S.). The shares were quoted at $1.97 Tuesday morning. Analyst Reni Benjamin writes that YM’s JAK1/JAK2 inhibitor represents the “principal value driver,” with a key [...]

GeneNews partner readying ColonSentry submission

Enzo Biochem’s (NYSE:ENZ) clinical labs division has completed validation testing of the GeneNews (TSX:GEN) ColonSentry pre-screening test for colorectal cancer and is in the final stages of submitting the data package to New York State regulatory authorities, according to a new report by Rodman & Renshaw. Analyst Reni Benjamin writes that the validation “demonstrated consistency [...]